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Mature B lymphocytes (B  cells) recognize antigens using their B  cell receptor (BCR) 
and are activated to become antibody-producing cells. In addition, and integral to the 
development of a high-affinity antibodies, B cells utilize the specialized major histocom-
patibility complex class II (MHCII) antigen presentation pathway to process BCR-bound 
and internalized protein antigens and present selected peptides in complex with MHCII 
to CD4+ T cells. This interaction influences the fate of both types of lymphocytes and 
shapes immune outcomes. Specific, effective, and optimally timed antigen presenta-
tion by B  cells requires well-controlled intracellular machinery, often regulated by the 
combined effects of several molecular events. Here, we delineate and summarize these 
events in four steps along the antigen presentation pathway: (1) antigen capture and 
uptake by B cells; (2) intersection of internalized antigen/BCRs complexes with MHCII 
in peptide-loading compartments; (3) generation and regulation of MHCII/peptide com-
plexes; and (4) exocytic transport for presentation of MHCII/peptide complexes at the 
surface of B cells. Finally, we discuss modulation of the MHCII presentation pathway 
across B cell development and maturation to effector cells, with an emphasis on the 
shaping of the MHCII/peptide repertoire by two key antigen presentation regulators in 
B cells: HLA-DM and HLA-DO.
Keywords: B  cell, MHC class ii, antigen processing, antigen presentation, invariant chain, HLA-DM, HLA-DO, 
germinal center
iNTRODUCTiON
In addition to their role as secretors of antibodies, B cells function as professional antigen-presenting 
cells (APCs) for CD4+ T cells by expressing cell-surface major histocompatibility complex class II 
(MHCII) molecules with bound peptide, the ligand of the α/β T cell receptor. MHCII-restricted 
antigen presentation by B cells plays a role in multiple immunological events. For example, recent 
evidence supports a model of sequential class II-restricted antigen presentation by thymic B cells to 
CD4+ thymocytes (1). In this scenario, resting IgD+/IgM+ B cells enter the thymus and undergo 
cognate interactions with CD4+ thymocytes and CD40-mediated B cell activation. This increases 
MHCII, CD80, and Aire expression, allowing B cell presentation of Aire-dependent antigens and 
negative selection of self-antigen reactive thymocytes. In another scenario, B cells contribute to the 
magnitude of primary CD4+ T cell responses (2) and to the development and expansion of Th2 
cytokine-secreting CD4+ T effectors (TEFF) (3). B cell division, hypermutation of immunoglobulin 
genes and engagement of T follicular helper cells (TFH) in the germinal center (GC) are directly 
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proportional to the amount of antigen captured and presented 
on MHCII (4, 5). Antigen presentation by B  cells also is criti-
cal to the generation and survival of memory CD4+ T cells (6). 
Recent work revealed a memory checkpoint when CD4+ TEFF 
require cognate antigen recognition for further differentiation 
into memory cells (7); at this checkpoint, B cell APC are required 
for driving TEFF to TFH (8). In murine models of type 1 diabetes 
and multiple sclerosis, antigen presentation by B cells contributes 
to disease pathogenesis (9, 10). Related to this, blockade of B cell 
antigen presentation is implicated as one mechanism underly-
ing efficacy of anti-CD20 therapy in CD4+ T  cell-mediated 
diseases, including autoimmune hepatitis, rheumatoid arthritis, 
and multiple sclerosis and mouse models of these diseases 
[(11–14) and references therein]. In addition, Jackson et al. have 
proposed that, in certain genetic settings, B cell presentation of 
self-antigens can initiate a break in CD4+ T cell tolerance (15). 
In summary, MHCII-restricted antigen presentation by B cells is 
critical to immune function in health and disease, highlighting 
the importance of a comprehensive understanding of the associ-
ated molecular mechanisms.
Here, we review current information on B cell antigen uptake, 
processing, and presentation as MHCII/peptide complexes at 
the cell membrane. We discuss antigen encounter in secondary 
lymphoid organs (SLOs), the role of the B cell receptor (BCR) in 
capturing antigen, and B cell polarization, in the case of antigen 
capture from the surface of other cells. We next cover BCR inter-
nalization, the targeting of BCR/antigen complexes to subcellular 
compartments for interaction with MHCII, the roles of B  cell 
proteases in invariant chain (Ii) degradation and generation of 
the peptide pool for MHCII loading. We review the shaping of 
the MHCII/peptide repertoire by HLA-DM and HLA-DO and 
the MHCII/peptide complex transport to the surface of B cells. 
Finally, the development and modulation of the MHCII pres-
entation pathway across the stages of B  cell differentiation are 
discussed.
In the mouse, B cells can be separated into B-1 and B-2 subsets, 
and recent studies argue that these are distinct lineages (16). 
B-1 cells (which likely have a human equivalent functionally) 
mostly arise in the fetal liver, self-renew in the periphery, and 
represent a small population that acts to achieve a rapid, early 
immune responses independent of T cell help (12, 16, 17). B-2 
cells (in mice and humans) are mainly produced in the bone 
marrow throughout life and predominate in the B  cell pool of 
SLO. B-2 cells are a key component of adaptive immune system, 
exhibiting antigen specificity and memory and mediating both 
T cell-independent and T cell-dependent antibody production. 
This review focuses on the class II antigen presentation pathway 
in B-2 cells (referred to as B cells in what follows).
THe BCR AND ANTiGeN eNCOUNTeR
A key component of immune surveillance is the circulation of 
naïve, mature B cells through SLOs. About 45% of naïve B cells 
migrate to the spleen to sample antigens present in the blood; 
a roughly equal number move to the lymph nodes to sample 
antigens drained from tissues, and the remainder move mostly 
to mucosa-associated lymphoid tissues (MALT), a key interface 
between the host and its environment (18). Within SLO, the 
B  cells localize to B  cell follicles in a chemokine (CXCR13)-
dependent manner and begin to sample antigen. How antigen 
traffics to the B cell zone depends on the SLO. In MALT, antigen 
is passed across the epithelial barrier into B cell zones (19). In 
the spleen, antigen draining from the splenic artery is intercepted 
in the marginal zone (MZ) by macrophages and dendritic cells 
(DCs), as well as by a unique class of MZ B  cells with innate-
like behavior and limited BCR diversity (20). All three types of 
APCs are capable of conveying antigen to B cell follicles in the 
periarteriolar lymphoid sheaths (21), but certain types of anti-
gens—especially repetitive bacterial polysaccharides and other 
T-independent type 2 antigens—are capable of activating MZ 
B cells directly (20) in a T-independent process (22, 23). In lymph 
nodes, antigen enters the subcapsular sinus (SCS) via afferent 
lymphatics and can reach B cell follicles in soluble form in the 
case of small antigens (<70 kDa) by movement through a conduit 
system that permeates the follicles (24, 25), or, for larger antigens 
and immune complexes, which are typically opsonized by com-
plement components, intercepted by complement receptors on a 
layer of SCS macrophages (SSMs) lining the follicular (FO) zone, 
and then passed between complement receptors on various APCs 
and non-specific B cells. Immune complexes ultimately become 
tethered to the membrane of a follicular dendritic cell (FDC) (26, 
27) for BCR scanning.
The BCR is composed of a membrane-bound immuno-
globulin (mIg) for antigen binding and a transmembrane Igα/Igβ 
heterodimer for signaling (28). The mIg consists of two immu-
noglobulin light (L) chains and two heavy (H) chains, which 
have variable numbers hydrophobic amino acid sequence motifs 
in their cytoplasmic tails, depending on the Ig isotype. Antigen 
recognition is mediated by the hypervariable regions of mIg VH 
and VL segments, which fold to form an antigen-binding site; 
signaling is mediated by the cytoplasmic immunoreceptor tyros-
ine activation motifs (ITAMs) of the associated Igα/Igβ heterodi-
mer. The spatial organization of BCRs on resting B cell surfaces 
and the effect of antigen engagement on this organization are 
incompletely understood. An early study showed by transmission 
electron microscopy that almost all plasma membrane-associated 
proteins, including BCRs, are present in clusters termed “protein 
islands” (29). Recently, point localization-based, super resolu-
tion fluorescence microscopy has provided information on the 
nanoscale spatial organization of BCRs on B cell surfaces at the 
level of individual BCRs. The results of three such studies (30–32) 
are consistent with models in which BCRs exist as monomers and 
in protein islands, and antigen encounter induces the coalescence 
of these into active signalosomes (33). By contrast, the results of 
Maity et al. (34) were interpreted to be consistent with a model 
in which BCRs exist in clusters on resting B  cell surfaces that 
are disrupted by antigen resulting in the initiation of signaling 
(35). Clearly much remains to be learned about the nanoscale 
organization of BCRs that will add to our understanding of the 
initiation of BCR signaling.
Ultimately, microclusters of BCR with bound antigen and 
other co-receptors visible by diffraction-limited light microscopy 
form and encounter the intracellular tyrosine kinase Lyn. Lyn 
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phosphorylates ITAMs on Igα and Igβ chains in BCR micro-
clusters, providing a docking site for the tyrosine kinase Syk 
which initiates intracellular signaling cascades that allow the 
B cell to internalize antigen (36) [see Internalization of BCR and 
Intersection with MHCII in the MHCII Compartments (MIICs)]. 
Evidence from high-resolution total internal reflection micros-
copy in conjunction with fluorescence resonance energy transfer 
in living B  cells argued that newly formed BCR microclusters 
perturbed the local lipid environment leading to the association 
of microclusters with a lipid raft probe and that this association 
facilitated the recruitment of Lyn to the BCR microclusters (37).
Soluble antigens are capable of initiating BCR clustering, 
but membrane-tethered antigens are more effective at inducing 
responses in vivo (38). This points to a critical role for FDCs and 
their use of long-term non-degradative compartments to store 
and recycle immune complexes and serve as an antigen depot 
(27). SSMs may also play a role in antigen presentation by convey-
ing opsonized antigen directly to B cells after intercepting it in the 
SCS (38). Cell biological data indicate that APC/B cell interaction 
involves two major features. First, once stimulated, the B  cell 
exhibits a membrane spreading and contraction response that 
assists with antigen aggregation and BCR microcluster formation 
and results in the formation of an immunological synapse with 
the APC (39, 40). Second, as the B cell separates from the APC, 
it extracts the target antigen from the surface of its partner cell.
The membrane-spreading response is accomplished within 
minutes of antigen contact by structural changes in the actin 
cytoskeleton. These changes involve cofilin-mediated severing 
of F-actin throughout the cell, followed by actin repolarization 
in the direction of the APC (41). The severing is thought to 
increase the mobility of cell-surface BCRs, assisting with forma-
tion of BCR/antigen microclusters and their movement into the 
center of the newly formed synapse (41, 42). The subsequent 
spreading response involves Arp2/3, resembling cell membrane 
extension of lamellipodia, whereas contraction requires dyneins 
and ERM proteins (40, 43). The microtubule cytoskeleton also 
changes shape in response to stimulation, with the microtubule-
organizing center migrating rapidly toward the site of contact, in 
a process dependent on CDC42 and PKCζ (44).
When contraction is complete, the synapse adopts a form with 
a central supramolecular activation complex (cSMAC), contain-
ing a large cluster of antigen-bound BCRs surrounded by a ring 
of actin and adhesion molecules, the peripheral SMAC (pSMAC) 
that tethers the B cell to the APC (43, 45). B cell extraction of 
antigen from the cSMAC is accomplished by mechanical force, in 
which B cells physically pull on synaptic antigen through the BCR 
and deform flexible membrane substrates to promote antigen 
internalization (46, 47). B cells also can extract antigen by release 
of degradative MHCII-containing vesicles, containing lysosomal 
proteases and lipases, into the pSMAC (44). Recent evidence sug-
gests that the mechanism of antigen extraction is dependent on 
the properties of the APC (48). The presence of MHC class II in 
the synapse along with lysosomal enzymes raises the possibility 
of peptide loading inside the synapse.
Due to the high affinity of their antigen receptor, B cells express-
ing specific BCRs require 1,000–10,000× less antigen to stimulate 
T cells compared to non-specific B cells (49). BCR affinity affects 
the efficiency of antigen collection from the surface of presenting 
cells (39), with contractile forces in the presenting cell setting a 
BCR affinity threshold for successful antigen capture (46). After 
ligand binding, high-affinity BCR forms larger microclusters for 
recruitment of signaling machinery (50). Lower affinity BCR also 
bind and internalize antigens, if a BCR avidity threshold, presum-
ably required for clustering and its consequences, is surpassed 
(51), as can occur with multivalent antigens, particularly at the 
surface of presenting cells (52).
Cross-linking of BCR by multivalent ligands initiates B  cell 
activation for antigen presentation. Evidence for activation by 
monovalent antigen has also emerged (31), with data suggesting 
a threshold for signaling that must be overcome by monovalent 
antigen to lead to antigen presentation. Membrane-bound 
monovalent antigen is apparently more effective than soluble for 
reaching this threshold [reviewed in Ref. (53)]. For naïve B cells, 
monovalent antigens can activate IgM-BCR, but immune com-
plexes are required for stimulation of IgD-BCR (35).
iNTeRNALiZATiON OF BCR AND 
iNTeRSeCTiON wiTH MHCii iN THe 
MHCii COMPARTMeNTS (MiiCs)
After antigen binding, B cells internalize antigens mainly through 
clathrin-dependent, BCR-mediated endocytosis (46, 54). Clathrin-
mediated endocytosis involves formation of clathrin-coated pits 
(CCPs), which pinch off plasma membrane to form intracellular 
vesicles. CCP formation is initiated by the phosphorylation of the 
adaptor, AP-2, which co-localizes with BCR/antigen clusters (55). 
The BCR binds AP-2 through its Igαβ subunits, the membrane-
proximal tyrosine of a YxxØ (Ø = bulky hydrophobic) motif on the 
Igβ being the most important residue for receptor internalization 
(56). Intracellular vesicle generation requires actin polymeriza-
tion and myosin activity (57, 58). After vesicle formation, clathrin 
disassociates, and the vesicle undergoes a cascade of biochemical 
changes, evolving into an early endosome and then into a late 
endosome. While most early endosomes are recycled back to the 
plasma membrane by Rab4, BCR signaling increases the rate of 
sorting into late endosomes via ubiquitination of BCR by c-Cbl 
and Cbl-b (59). Rab7 shepherds the transition of early endosome 
to late and appears to be directly modulated by BCR signaling 
(60). The final stage is delivery of vesicles carrying the antigen-
bound BCR to peptide-loading compartments.
Reagents that cross-link the BCR and initiate signaling are 
10× more efficient in delivering BCR to MHCII peptide-loading 
compartments than monovalent reagents (61). Lyn kinase activ-
ity associated with BCR signaling directly enhances endocytosis 
via phosphorylation of the clathrin heavy chain, which promotes 
its association with actin-coupling clathrin light chains (62, 
63); BCR signaling also results in tyrosine phosphorylation 
of CCP-associated proteins (epsin15, epsin2, etc.) and down-
stream proteins (e.g., Vav, Btk) that play roles in both signaling 
and endocytosis (60, 64). BCR signaling promotes receptor 
endocytosis, but the exact roles for Igαβ motifs remain elusive, 
as signaling and endocytosis compete for the same motifs (56). 
Indeed, some evidence supports a model in which distinct BCR/
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antigen complexes mediate signaling and antigen internalization 
(65). Internalization of BCR inhibits signaling, as localization in 
endosomal compartments reduces surface BCR and abrogates the 
activity of signaling proteins, such as Lyn, Syk, and BLNK (66).
Endocytosed BCR/antigen complexes intersect with newly 
synthesized MHCII en route to the cell surface. Nascent MHCII 
αβ heterodimers are generated in the endoplasmic reticulum (ER) 
and rapidly associate with trimers of the type II membrane glyco-
protein, Ii (CD74), a dedicated MHCII chaperone. Interaction with 
Ii facilitates MHCII folding and inhibits ligand binding to class II 
in the ER. Ii contains a peptide sequence (aa 81–104), referred to 
as the class II-associated invariant-chain peptide (CLIP) region, 
which non-covalently binds the MHCII groove. Four Ii isoforms 
exist: p41 and p43, which are expressed at low levels in B cells 
compared to other APC, and p33 and p35. p35 associates with 
clathrin-associated adaptor proteins; however, if all Ii species are 
p33, the complex can exit the ER as a pentamer (67). Export out of 
the ER occurs when all the retention motifs present in the trimer 
are “cancelled” (68). Trafficking of egressed MHCII–Ii complex, 
first to the trans-Golgi network, is controlled by cytosolic sort-
ing tags. Recognition by AP-2 of two dileucine motifs in the Ii 
cytosolic domain enables αβIi sorting to clathrin-coated vesicles, 
and eventual localization to MIICs (69, 70). The exact definition 
of MIIC has been a matter of debate, but these compartments can 
be broadly characterized as late endosomal structures enriched 
in proteolytic enzymes and disulfide reductases and with suffi-
ciently low pH to activate proteases involved in Ii degradation (see 
below) and antigen processing (54). The compartments exist in 
a several forms—multivesicular bodies (MVBs) or multilamellar 
structures—that are generally LAMP-1 positive (71).
Many Ii-mediated events are common to professional 
MHCII-expressing APC. However, lack of Ii in B cells and DCs 
in Ii-deficient mice shows some differential impact on MHCII-
restricted antigen presentation. Some Ii-deficient DCs undergo 
normal maturation and present a broad range of peptidic epitopes 
from antigen internalized by fluid-phase endocytosis (72). By 
contrast, Ii is required for presentation of BCR-internalized anti-
gen (73), and Ii-deficient B cells failed to present Ag-generated 
epitopes unless these epitope peptides were exogenously sup-
plied (74), consistent with findings that, in B cells, Ii controls the 
transport of MHCII to and from MIIC (75) where BCR-delivered 
antigens are concentrated.
The intersection of antigen-bound BCR and MHCII appears 
to be actively promoted, as BCR binding by Fab′2 is associated 
with movement of MHCII to LAMP-1+ MVB vesicles (76) and 
ligated BCR and Ig-α/Ig-β also localize to these compartments, in 
a ubiquitin-dependent manner (77). Interaction of internalized 
BCR/antigen with intracellular MHCII was observed in pull-
downs using biotin-labeled antigen (78). Strikingly, a rare (10%) 
conformation of MHCII seems to be a predominant conformer 
in complex with the BCR/antigen. This conformer (defined by the 
Ia.2 epitope) is highly effective for T cell activation, is enriched 
in lipid rafts, and stimulates intracellular calcium signaling in 
B  cells (79, 80) Selectivity of the BCR/antigen for this MHCII 
conformer may contribute to the efficiency of BCR-mediated 
antigen presentation.
GeNeRATiON OF THe MHCii/PePTiDe 
RePeRTOiRe: PROTeASeS AND 
ReGULATiON OF PePTiDe LOADiNG
Proteolytic events relevant for MHCII antigen presentation in 
B  cells include processing of Ii and processing of endogenous 
and exogenous antigens, including BCR/antigen (81). Key 
enzymes implicated in epitope generation for MHCII presenta-
tion include lysosomal proteases that can be classified based on 
their catalytic mechanism into four major families (Table  1): 
(1) the cysteine cathepsins with a papain-fold (B, C, F, H, K, 
L, O, S, V, W, and X); (2) the aspartyl cathepsins D and E; (3) 
the serine cathepsins A and G, and (4) single member family of 
asparagine endopeptidase (AEP), a cysteine protease grouped 
with the caspases (82). In addition, gamma-interferon-inducible 
lysosomal thiol reductase (GILT) cleaves protein disulfide bonds 
(83). Cathepsins are synthesized as inactive zymogens that get 
modified by addition of mannose-6-phosphate residues (M6P), 
allowing recognition by M6P receptors in the trans-Golgi 
network and delivery to endosomal/lysosomal compartments. 
Cathepsin activation requires catalysis by other lysosomal pro-
teases or by autocatalysis under certain circumstances, such as 
low pH or presence of glycosaminoglycans. Lysosomal proteases 
of the cysteine type have optimal activity at acidic pH, but other 
proteases are active over a range of pH. Inactivation occurs by 
protease degradation or by oxidation. Levels of expression and 
activity of cathepsins are controlled by multiple factors, including 
mRNA levels, local pH, and other protein factors that influence 
cathepsin trafficking and activation. For example, endogenous 
inhibitors like cystatins, stefins, tyropins, and serpins also regu-
late cathepsin function, although it appears that cystatins do not 
control antigen presentation (84).
Proteolytic processing of Ii is required for loading of antigen 
peptides onto MHCII. Ii processing, which starts with formation 
of a 22 kDa leupeptin-induced protein, can be initiated by AEP 
(94). The second intermediate, 10 kDa fragment small-leupeptin-
induced protein (SLIP) is then cleaved to generate the 25aa CLIP 
fragment. Cat S is the key component for converting the 10 kDa 
fragment into CLIP. In the human thymus, Cat V or L2 (Cat L in 
mice) is the main protease converting SLIP to CLIP. Studies of 
B cells and DCs from animals deficient in Cat S showed accumu-
lation of surface MHCII with the 10 kDa Ii fragment (100), and 
reduced antigen presentation. In mice, in the absence of Cat S and 
L, Cat F in macrophages can generate CLIP, indicating cathepsin 
redundancy (82).
The crystallizable fragment (Fc) and antigen-binding frag-
ment (Fab) domains of immunoglobulin remain largely intact in 
the MIIC of B cells (101, 102). Notably, however, the two domains 
can be immunoprecipitated separately, and co-precipitation of 
antigen with the Fab domain can be detected (101). This find-
ing implies that proteolytic enzymes resident in the MIIC cleave 
intact immunoglobulin. In bone marrow-derived APC (over 
80% macrophages), Cat B appears important for degradation of 
immunoglobulins that are taken up by Fc receptors (85).
Characterization of lysosomal proteases in B  cells is still 
incomplete. Furthermore, one shortcoming of some studies on 
TABLe 1 | Lysosomal proteases involved in MHC class ii antigen processing.
Lysosomal 
protease
Type/activity Distribution in immune cells involved in (reference)
Cathepsin B Cysteine/endo- 
and exopeptidase 
(carboxydipeptidase)
BCLs, DCs, and macrophages Processing of immune complexes internalized via FcγR (85)
Cathepsin F Cysteine/endopeptidase Macrophages Ii processing in absence of Cat S and L (86)
Cathepsin H Cysteine/endo- 
and exopeptidase 
(aminopeptidase)
Ubiquitously expressed Octapeptid (mini-chain) confers aminopeptidase activity; without the 
mini-chain function similar to Cat S (87)
Cathepsin S Cysteine/endopeptidase BCLs, DCs, macrophages, and epithelial cells Converting the 10-kDa SLIP fragment from Ii into CLIP; processing of 
exogenous and endogenous antigen (88)
Cathepsin V or L2 
(human homolog of 
mouse cathepsin L)
Cysteine/endopeptidase Cortical human thymic epithelial cells; testis Ii proteolysis in thymus (89)
Cathepsin D Aspartic/endopeptidase Ubiquitously expressed; also secreted Destructive processing of myoglobin (90); there is evidence of 
redundancy among the aspartic cathepsins (Cat D and E)
Cathepsin E Aspartic/endopeptidase BCLs, B cells upon activation, monocyte-
derived DCs, myeloid DCs, Langerhans cells
Processing ovalbumin; processing of TTC (91); processing of 
myoglobin (90); there is evidence of redundancy among the aspartic 
cathepsins (Cat D and E)
Cathepsin A Serine/exopeptidase 
(carboxypeptidase)
Widely expressed, including primary B cells, 
BCLs, myeloid DCs, plasmacytoid DCs (92)
Removes amino acids from proteins or peptides C-terminal; may be 
important for fine trimming of peptides (92)
Cathepsin G Serine/endopeptidase Neutrophils, mast cells, B cells (endogenous/
exogenous source), monocytes, myeloid 
DCs, plasmacytoid DCs; granule associated
Destructive processing/processing of MBP in primary B cells (93)
Asparagine 
endopeptidase 
Cysteine/endopeptidase BCLs; low in B cells; thymic CD11c+ DCs; 
F4/80+ thymic macrophages
Initial processing of Ii chain (94); in vitro intracellular processing of TTC 
(95); in vitro destructive processing of MBP (96, 97); not necessary for 
TTC processing in vivo (98); processing of Cat B, H, and L (99)
BCLs, B cell lymphoblastoid line; DCs, dendritic cells; Ii, invariant chain; SLIP, small-leupeptin-induced protein; CLIP, class II-associated invariant-chain peptide; TTC, tetanus toxin, 
C-fragment; MBP, myelin basic protein.
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B cell proteases is the use of B lymphoblastoid cell lines (B-LCL), 
which may not reflect the endo/lysosomal environment in pri-
mary B cells. For example, B-LCL degrade myelin basic protein 
(MBP) by AEP, but human primary B  cells have low level of 
AEP activity and instead use exogenous Cat G (103), a granule-
associated protease that binds the B cell surface via a thrombin-
like receptor and is internalized into endosomes (93). In addition, 
human B-LCL contain active CatS, CatB, and CatD, whereas none 
of these cathepsins are detected in resting primary human B cells 
(103). Cat E expression is enhanced in primary tonsillar B cells 
after activation with Staphylococcus aureus (104); similarly, PMA 
activation increases expression of Cat E in primary B cells from 
blood and increases presentation of tetanus toxin C-fragment to 
T cells (91). Thus, some of the differences between B-LCL and pri-
mary B cell lysosomal protease content may be due to activation 
state. Murine primary B cells express lysosomal GILT, and GILT 
activity decreases Cat S expression and function (105), suggesting 
that GILT participates in control of cathepsin activity in B cells.
The cathepsin profile of B  cells has similarities to the DC 
profile (Table 1). B cells and DCs have lower levels of lysosomal 
proteases, with corresponding lower proteolytic activity, com-
pared to macrophages. These differences appear to be specific 
to the lysosomal proteases and cannot be ascribed to number of 
lysosomes. Although the rate of antigen internalization is similar 
between DCs and macrophages, the rate of proteolysis is slower in 
DCs. For test antigens, protection from degradation is associated 
with enhanced presentation to T cells (106).
Studies of mice deficient for specific proteases show that 
proteases can influence the repertoire of peptides presented 
by MHCII. However, it is largely unknown if these effects 
are mediated by direct participation of specific proteases in 
endosomal antigen processing or predominantly influence 
Ii processing. For example, a series of studies showed that in 
B cells, as well as in DCs, Cat S does not directly influence the 
generation of most peptides presented by MHCII, but some 
peptides are affected [reviewed in Ref. (88)]. An additional 
challenge is that degradation of a given protein may require a 
series of proteases. For example, degradation of MBP in vitro is 
initiated by AEP and Cat S, and intermediates are subsequently 
degraded by other proteases including Cat S, D, and L (96). 
Data from an in vitro antigen-processing model system using 
only three cathepsins (Cat B, H, and S) argued that sensitiv-
ity to these cathepsins, the structure of proteins, strength of 
peptide binding to HLA-DR, and HLA-DM susceptibility 
(see below) were all factors that influence which peptides are 
presented by MHCII (107). This in vitro system recapitulated 
generation of naturally processed peptides from test proteins, 
suggesting its potential value for epitope prediction and for 
modeling mechanistic steps in antigen processing for MHCII 
cargo (108). Determination of the in  vivo roles for specific 
proteases remains a subject of on-going work.
Availability of antigen for processing is influenced BCR affin-
ity. Higher affinity binding allows delivery of protected regions 
to later compartments for peptide generation and binding to 
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nascent MHCII (although highest affinity binding may suppress 
epitope availability), while lower affinity allows release of antigen 
in earlier compartments and generation of peptides that can 
bind recycling MHCII (109). For certain antibodies with highly 
pH-dependent binding to antigen, lower pH of the later com-
partments may greatly facilitate epitope generation (110). BCR 
binding suppresses some and enhances availability of other T cell 
epitopes, with both types of determinants within the region of the 
antigen “footprinted” by the antibody (111). BCR-bound antigen 
can persist in B cells, providing a source of peptide longer than 
antigen taken up by fluid phase (112).
Like other professional APCs, B cells express a non-classical 
class II molecule, HLA-DM (DM; H2-M in mice), with high-
est concentrations in late endocytic compartments. Despite 
the structural similarity with classical MHCII, DM does not 
directly bind peptides (113); instead, it modulates the peptidome 
via a catalytic mechanism (114, 115). DM function is crucial; 
DM-null APCs are defective in MHCII antigen processing and 
presentation (116) and DM-deficient mice present a skewed 
peptide repertoire, impairing selection of CD4+ T cells (117). 
The generally accepted function of DM is that it stabilizes a 
peptide-receptive form of MHCII by a transient association (118, 
119); and this temporary DM/MHCII interaction facilitates the 
removal of weak binding peptides, such as CLIP and cryptic 
epitopes, while promoting the loading of high-affinity peptides 
that mostly become immunodominant epitopes for MHCII 
presentation at the surface of B cells (120–123). DM-regulated 
epitope selection (DM editing) is a pH-dependent process with 
pH optima (4.5–5.5), recapitulating late endosomal–lysosomal 
conditions in MIICs (124, 125).
Another non-classical class II molecule, HLA-DO (DO), 
also plays an essential role in antigen presentation in B  cells 
(126–129), as knockout of the murine DO homolog, H2-O, leads 
to immunodeficiency and autoimmunity that are directly related 
to dysfunction of antigen presentation by bone marrow-derived 
cells (130). Although DO is structurally quite homologous to 
classical MHCII, there is no evidence that it can directly present 
peptides. However, DO mimics MHCII in binding to the same 
site on DM, such that it blocks the catalytic action of DM on 
MHCII/peptide complexes (113, 131). The requirement for DM 
inhibition by DO in antigen presentation in a restricted group of 
APCs (132) implies unique features of the MHCII peptidomes in 
these cells, especially B cells.
The affinity of DO/DM binding (nanomolar) (125, 133) is 
1,000- to 10,000-fold stronger than that of the transient bind-
ing of MHCII to DM (micromolar) (131), and DO requires the 
tight association with DM to exit the ER for translocation to its 
lysosomal destination (134). The molecular interaction between 
intact DO and DM is pH insensitive, even at the lysosomal pH 
(125). This raises questions as to how DO-associated DM is 
freed to edit MHCII-associated peptide cargo, and what role 
DO plays to modulate the B cell MHCII peptidome. The stoichi-
ometry of DM:MHCII is a critical factor in the pH-dependence 
of DM editing (125). DM abundance can compensate for 
the reduction in its enzymatic activity at pH >  5.5, and this 
potentially allows DM editing in high DM-expressing APCs, 
like B cells, to emerge outside late endocytic MIIC. Therefore, 
DO likely serves as a regulator to control the abundance of free 
DM and keep DM function focused on acidic MIICs (also see 
GC B Cells).
Multiple mechanisms have been postulated to explain how 
DO/DM complexes facilitate peptide loading onto MHCII 
[details are reviewed in Ref. (129, 135–137)]. Recent evidence 
argues that DO/DM complexes are inert for peptide exchange 
catalysis, but that in lysosomal conditions, low pH promotes 
denaturation of DO within the complex to elevate the level of 
free, catalytically active DM (125, 133). pH-dependent DO 
removal is an irreversible process that may be associated with 
many antigen-triggered events in the B  cell, including the 
acidification of lysosomes, BCR signal-mediated transcrip-
tional modifications of MHCII or the class II transactivator 
(CIITA), and redistribution of MHCII proteins within a 
multivesicular MIIC. An alternative view, that DO optimizes 
presentation of DM-resistant peptides through direct inter-
action with a peptide-receptive form of MHCII, has been 
presented (138).
The cytoplasmic tails of both DM and DO contain lysosomal 
targeting motifs. Interestingly, without DO, DM can reside 
outside of lysosomes, for instance, on the surface of immature 
myeloid DCs (139) or on secreted exosomes (140). Although no 
high-resolution imaging data are available, these studies at least 
suggest that the sorting motif on DO constrains the intracel-
lular location of DO/DM complexes to lysosomes, where DM 
is further distributed away from internal membranes (source 
of exosomes) to the limiting membrane (140, 141). As (usually 
foreign) antigens associated with BCRs are typically protected 
from proteolysis at early endosomal pH, DM editing likely is 
unnecessary at the earliest stages of antigen endocytosis in 
B cells. Lysosome-oriented trafficking together with functional 
inhibition conferred by DO would focus DM editing on epitopes 
derived from BCR/antigen complexes that also localize to MIICs. 
DO-regulated trafficking may rely on the ubiquitination of cyto-
plasmic tails of DO heterodimers by, for example, a MARCH 
family E3 ligase (142).
The ectodomain of DM has reduced activity at pH 4.6 likely 
due to denaturing of free DM (125). This implies that DO may 
reciprocally chaperone and stabilize DM through tight associa-
tion and maintain DM levels in lysosomes; this effect is also sug-
gested by evidence in DO-expressing DCs from transgenic mice 
(143). Such bi-directional chaperoning would persist until an 
antigen exposure drives DO removal in MIIC. In agreement with 
this hypothesis, several studies have shown a concomitant decline 
of DM and DO during B cell activation (126, 127), although the 
DM:DO ratio increases in favor of DM editing.
As DO/DM and BCR/antigen complexes meet in MIICs, 
DM may also function in facilitated antigen hand-off from BCR 
to MHCII proteins. The recent findings that DM and mIg co-
precipitate from cell lysates and that soluble recombinant DM and 
Fab fragments (but not Fc fragments) co-precipitate in vitro raise 
the possibility of a multimeric class II peptide-loading complex, 
including membrane Ig, DM, and MHC proteins (144). Figure 1 
summarizes key events described in Section “Generation of the 
MHCII/Peptide Repertoire: Proteases and Regulation of Peptide 
Loading” of the review.
FiGURe 1 | Current model of the regulation of antigen processing and presentation in B cells. B cell antigen uptake by membrane immunoglobulin (mIg) is 
substantially (1,000×) more efficient than by fluid-phase endocytosis. Binding to mIg protects regions of antigens from proteolysis at the early stages of the 
endocytic pathway. As pH decreases along this pathway, Ig can be processed into antigen-binding fragment (Fab) and crystallizable fragment (Fc) domains. 
Antigens become available for peptide generation through a combination of unfolding, proteolytic processing, and release from Ig. MHCII/invariant chain (Ii) 
complexes, DM and its inhibitor, DO, are generated in the endoplasmic reticulum (ER) and transported through the Golgi to late endosomal compartments, termed 
MIIC. Although Ii processing begins as MHCII/Ii complexes traverse earlier endocytic compartments, exchange of the final Ii remnant peptides (CLIP) bound to the 
MHCII peptide binding groove with antigenic peptides or self-peptides is inefficient before MHCII enters MIIC. Mechanisms limiting peptide exchange until this stage 
include (1) DO significantly inhibits DM catalysis of peptide loading and (2) Fab-associated antigen fragments are largely protected from proteolysis to peptides. At 
late stages of these pathways, lysosomes merge with MIIC. This generates the highly acidic condition that favors denaturation and degradation of DO and Fab, and 
DM-mediated peptide exchange. Most derivatives of self-proteins internalized without mIg cannot survive endosomal/lysosomal proteolysis. Arrows indicate protein 
trafficking through different intracellular compartments (indicated by colors) along each pathway. Dotted lines indicate unfavorable processes. ECF, extracellular fluid; 
MHCII, major histocompatibility complex class II proteins; MIIC, MHCII compartments; CLIP, class II invariant-chain-derived peptides.
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MHCii/PePTiDe COMPLeX TRANSPORT 
TO THe SURFACe
The molecular details of transport of newly loaded MHCII/pep-
tide complexes from the MIIC to the cell surface are not deline-
ated in mechanistic detail for any APC, although clearly CLIP 
replacement with other peptides is not a requirement for egress 
from MIICs. More is known about the regulation of MHCII sur-
face expression and its relationship to recycling of newly synthe-
sized MHCII in complex with peptide. Available data argue that 
B cell activation does not influence the endocytosis of surface 
MHCII, yet it clearly alters the level of MHCII expression. Cho 
et al. demonstrated that internalized MHCII efficiently recycles 
in activated B cells, but not in resting B cells. The lack of MHCII 
recycling in these cells is a consequence of oligoubiquitination 
of a single conserved lysine (K225) in the C-terminal cytosolic 
tail of the MHCII β chain by the E3 ubiquitin ligase MARCH1. 
Further, MHCII ubiquitination promotes sorting to MVB and 
turnover of MHCII in lysosomes. Upon antigen ligation of BCRs, 
MARCH1 expression and MHCII ubiquitination is halted, 
enabling MHCII escape from degradation, rapid recycling, and 
increased surface expression. The activation induced boost in 
MHCII also promotes the ability of B cells to present the activat-
ing antigens (145).
MHCii ANTiGeN PReSeNTATiON OveR 
THe SPAN OF B CeLL DeveLOPMeNT
early B Cell Development
Early stages of B cell development in the bone marrow (pro- and 
pre-B cells) are defined by stepwise rearrangement of V, D, and 
J gene segments at the Ig heavy and light chain loci [(146); see 
Figure 2]. The first BCR complex, expressed at the pre-B cell stage, 
is composed of the heavy-chain gene product with a surrogate 
light chain (λ 5-Vpre-B), together with the Igα/Igβ heterodimer 
(147, 148). Interestingly, antigen-presenting machinery is already 
present at the pro- and pre-B stages, as CIITA is expressed and 
drives expression of MHCII, HLA-DM, and Ii (149, 150). The 
presence of most MHCII pathway components (except DOβ) in 
the absence of mature BCR raises the question of their potential 
function in B  cell development. Strikingly, the Ii N-terminal 
domain (aa 1–82) has an alternate activity in B  cells that does 
not relate to its role in antigen presentation. Ii-deficient mice 
FiGURe 2 | expression of components of the major histocompatibility complex class ii (MHCii) antigen presentation pathway across the stages of 
B cell development. Early B cells (pro-B, pre-B, and immature-B-cell) reside in the bone marrow. These stages are defined by the rearrangement of V, D, and J 
gene segments at the Ig heavy and light chain loci. At the pre-B cell stages, the pre-BCR is composed of a heavy chain paired with the surrogate light chain (λ 
5-Vpre-B), together with signaling components Ig-α and Ig-β. The mature IgM-B cell receptor (BCR) emerges on immature B cells that exit the BM. They migrate to 
the spleen as transitional B cells and mature to naïve, pre-immune cells of the follicular (FO) B subset, found in the blood and secondary lymphoid organs. Upon 
immunological challenge, naïve FO B cells that successfully process and present MHCII-bound antigen to CD4+ T cells, differentiate into centroblasts and 
centrocytes organized in germinal centers. Following BCR affinity maturation, selected B cells further differentiate into long-lived memory B cells or antibody-
secreting plasma cells. Relative expression of the MHCII antigen presentation machinery components is represented by color intensity.
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show an arrest in B cell development with an enlarged popula-
tion of immature IgDlow CD23low transitional B cells. When the 
Ii N-terminal domain alone is expressed in transgenic mice, 
MHCIi trimer formation and egress from the ER is recovered, 
but MHCII/peptide formation and surface expression is not 
restored (151). Rather, this Ii domain initiates a signaling cascade, 
resulting in NFkB activation and B cell maintenance (152). The 
intramembrane protease SPPL2a (presenilin homolog signal-
peptide-peptidase-like 2a) catalyzes the generation of this Ii 
fragment in mice and human B cells (153) Ii has third role for 
B cells as the receptor for macrophage migration inhibitory factor 
and interaction leads to signaling cascade that promotes B cell 
chemotaxis and survival (154).
In contrast to effects of Ii knock out, B cell development is only 
subtly altered in MHCII-deficient mice. In these mice, a mature 
B  cell population is established, although the overall number 
of mature B cells and their capacity for antigen presentation is 
impaired (155, 156). B cells also reach the mature stage in bare 
lymphocyte syndrome patients, who lack MHCII expression due 
to mutation of CIITA (157). In DM-deficient mice, B cells mature, 
but display a reduced response to antigen (117). In light of these 
results, Chen and Jensen (156) proposed that the presence of 
the class II antigen presentation machinery in pre-, pro-, and 
immature BM B cells serves as a mechanism to induce peripheral 
CD4+ T cell tolerance through presentation of peptides from self-
antigens (156). Low or no MHCII/CLIP complexes are detected 
on these B cells, implying that MHCII undergoes at least one pep-
tide exchange cycle to remove CLIP and bind self-peptides. This 
possibility is consistent with expression of DM without DO at 
these early stages. As CD40 is not expressed on immature B cells, 
recognition by autoreactive T cells would likely result in anergy 
or deletion. Additional work is needed to confirm this hypothesis.
immature Transitional and Naïve B Cells
Following BCR maturation, IgM is expressed on the surface 
of immature B cells that exit the BM and migrate to the spleen 
as transitional B  cells (12). Close to 85% of the original B  cell 
repertoire is eliminated by negative selection of cells expressing 
autoreactive BCR. Transitional B cells further mature to naïve/
pre-immune B cells of the FO B subset in blood and SLO or to 
MZ B cells of the splenic white pulp (158, 159). Expression of DO 
emerges in naïve (IgM+/IgD+/CD40+) B cells (142). DM levels 
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are relatively stable throughout B cell development, leading to a 
high DO:DM ratio at this stage. This ratio inhibits DM activity, 
particularly in early, higher pH endosomal compartments, which 
are accessed by fluid-phase endocytosis of self-proteins. Reduced 
DM peptide exchange activity results in high levels of MHCII/
CLIP complexes on naïve B cells. DO activity may thus limit the 
MHCII/self-peptide repertoire in naïve circulating B cells, reduc-
ing the possibility of recognition by autoreactive T cells (128, 160).
GC B Cells
Presentation of MHCII/peptide by FO B cells in the lymph node 
mediates cognate interaction with CD4+ T  cells, co-stimulated 
by CD40–CD40L interaction. Initial T  cell contact drives B  cell 
differentiation into centroblasts and centrocytes organized in GCs, 
with B  cell-rich dark zones, where centroblasts undergo somatic 
hypermutation, yielding clonal variants of GC B cells with modified 
antigen affinity and specificity (161). Centroblasts further differenti-
ate into centrocytes and enter the GC light zone, where encounters 
with FDC reintroduces antigen to the modified BCR. Antigen 
uptake and presentation permits cognate interaction with TFH cells, 
in proportion MHCII/peptide levels (4). Centrocytes with higher 
affinity for antigen are selectively preserved, whereas those with 
reduced BCR affinity are deleted. Additionally, a subset of centro-
cytes undergoes class-switch recombination for expression of IgG, 
IgA, or IgE (161–163). Reduced DO expression marks GC entry of 
B cells and is primarily driven by post transcriptional events, such 
as ubiquitination by MARCH9 (126, 127, 142). Centrocytes likely 
benefit from maximum DM editing both kinetically and stoichio-
metrically to achieve high levels of stable MHCII/peptide complexes 
and garner T cell help. Such a high level of DM activity cannot simply 
stem from transcriptional upregulation; indeed, GC B cells express 
slightly lower levels of DM protein than naïve or memory B cells 
(127). This suggests that the boost in DM editing originates from 
pre-existing inactive DM that was most likely associated with DO.
Major histocompatibility complex class II/peptide complexes 
on the surface of GC centroblasts are ubiquitinated and targeted 
for degradation, whereas centrocytes express long-lived MHCII/
peptide complexes (164). The MHCII turnover in these cells is 
controlled by oligoubiquitination of the MHCII β chain cytosolic 
tail by MARCH1. MHCII ubiquitination prevents the accumu-
lation of older MHCII/peptide complexes in GC centroblast 
B cells and allows antigen captured via affinity modulated BCR 
to be presented on newly expressed MHCII, thus reporting on 
the SHM process (165). Once cells move to the light zone as 
centrocytes, MHCII/peptide complexes on the cell surface are 
stabilized, facilitating productive interactions with CD4+ T cells 
during selection for high-affinity clones.
Post GC Memory B and Plasma Cells (PC)
Centroblasts and centrocytes circulate between the light and dark 
zone until an optimal level of BCR affinity is achieved, and the 
selected B cells can further differentiate into long-lived memory 
B cells or antibody-secreting PC (161). Memory B cells express 
DO and DM and reestablish a higher DO:DM ratio compared to 
GC B cells. The model of irreversible DO removal (see Generation 
of the MHCII/Peptide Repertoire: Proteases and Regulation of 
Peptide Loading) need not conflict with the observation that 
memory B cells leaving the GC have upregulated DO levels (126, 
127), given the rapid differentiation and cell division of pheno-
typically polarized GC B  cells (166). Asymmetric segregation 
of proteins relevant for T cell interaction could allow polarized 
GC B  cells to give rise to daughter cells with distinct fates: an 
effector-prone cell that bears most of free DM capable of antigen 
presentation to T  cells, and a memory-prone cell that inherits 
most of the DO/DM complex and exits GC with high DO:DM 
ratio. Surface MHCII/CLIP levels on memory B cells are lower 
than levels on naïve cells (167); this finding could result from sta-
bility of MHCII/peptide complexes acquired during the GC stage.
Studies of mice lacking MHCII expression in memory 
cells showed impaired ability of these cells to differentiate into 
PC upon antigen restimulation (168). During the B memory 
response, B/T cell cognate interaction again promotes selective 
activation of affinity matured memory B cells that will yield PC 
secreting high-affinity antibodies. After B cell differentiation into 
PC, expression of CIITA, which controls most components of the 
class II processing pathway, is repressed, yielding marked reduc-
tions in the levels of DM, DOα, Ii, and MHCII (167). Though 
DOβ expression is not regulated by CIITA, the lack of DOα 
expression together with DO requirement for DM to egress from 
the ER results in loss of functional DO.
CONCLUSiON
Many essential molecular mechanisms modulating the protein 
dynamics of MHCII-restricted antigen presentation by B cells have 
come to light in recent years, revealing the elegance of this system 
for carefully regulated functions across the span of the B cell life 
cycle. In parallel (though not the focus of this review), emerging 
evidence indicates a critical role for B cell antigen presentation func-
tion in various immune and autoimmune reactions. Nonetheless, 
key questions remain to be answered. What initiates and regulates 
fluid-phase endocytosis in B cells and what is the role of this process 
in early B cells that lack mature BCR? What molecular events medi-
ate independent and interdependent signaling and antigen inter-
nalization downstream of antigen binding to the BCR? How does 
antigen binding influence the architecture of the endocytic pathway 
and the composition and protease content of intracellular compart-
ments? What factors in addition to pH influence the DM:DO ratios 
in endocytic compartments? What are the mechanisms involved 
transport to the surface of MHCII/peptide complexes? Are 
there unique features of the MHCII pathway in memory B cells? 
Undoubtedly, B  cell-mediated MHCII antigen presentation is an 
exciting and important field to watch in the coming years.
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